Deep brain stimulation is a potential option for patients with treatment-refractory depression. Deep brain stimulation benefits have been reported when targeting either the subgenual cingulate or ventral anterior capsule/nucleus accumbens. However, not all patients respond and optimum stimulation-site is uncertain. We compared deep brain stimulation of the subgenual cingulate and ventral anterior capsule/nucleus accumbens separately and combined in the same seven treatment-refractory depression patients, and investigated regional cerebral blood flow changes associated with acute and chronic deep brain stimulation. Deep brain stimulation-response was defined as reduction in Montgomery-Asberg Depression Rating Scale score from baseline of ≥50%, and remission as a Montgomery-Asberg Depression Rating Scale score ≤8. Changes in regional cerebral blood flow were assessed using [ 15 O]water positron emission tomography. Remitters had higher relative regional cerebral blood flow in the prefrontal cortex at baseline and all subsequent time-points compared to non-remitters and non-responders, with prefrontal cortex regional cerebral blood flow generally increasing with chronic deep brain stimulation. These effects were consistent regardless of stimulation-site. Overall, no significant regional cerebral blood flow changes were apparent when deep brain stimulation was acutely interrupted. Deep brain stimulation improved treatment-refractory depression severity in the majority of patients, with consistent changes in local and distant brain regions regardless of target stimulation. Remission of depression was reached in patients with higher baseline prefrontal regional cerebral blood flow. Because of the small sample size these results are preliminary and further evaluation is necessary to determine whether prefrontal cortex regional cerebral blood flow could be a predictive biomarker of treatment response.
Introduction
Major depressive disorder (MDD) is a common psychiatric disorder affecting an estimated 350 million people globally. It is severely debilitating and characterised by low mood, decreased energy, impaired cognition and increased risk of suicide (World Health Organization, 2016) . MDD can be effectively treated in the majority of patients with either antidepressant medication or psychotherapy (Mayberg et al., 2005) . However, 20-30% of patients fail to respond to standard therapies (Mayberg et al., 2005; Millet et al., 2014; Morishita et al., 2014) .
A possible alternative treatment for this treatment-refractory depression (TRD) is deep brain stimulation (DBS). DBS aims to modulate dysfunctional neuronal networks by surgical placement of stimulating electrodes (Krishnan and Nestler, 2010) . Promising antidepressant effects of DBS have been reported when targeting either the subgenual cingulate gyrus (SGC), comprising Brodmann areas 25 (Cg25) and 24 (Cg24) (Berlim et al., 2014; Holtzheimer et al., 2012; Lozano et al., 2008; Mayberg et al., 2005; Puigdemont et al., 2012) , or the ventral anterior capsule/ nucleus accumbens (VAC/NAcc) (Bewernick et al., 2010 (Bewernick et al., , 2012 Kubu et al., 2013; Malone et al., 2009; Millet et al., 2014; Nauczyciel et al., 2013; Schlaepfer et al., 2008) . These targets are in close anatomical and functional relationship, and data from neuroimaging studies can be used to argue for either of these targets (Schlaepfer and Bewernick, 2013) .
Cg25 glucose metabolism is increased in MDD and remission is associated with normalization of this hypermetabolism (Schlaepfer and Bewernick, 2013) . DBS of Cg25 has shown a response rate (i.e. at least 50% reduction in the Hamilton Depression Rating Scale) of 62.5% after 12 months (Puigdemont et al., 2012) , 60% after three years, and 55% between 3-6 years (Kennedy et al., 2011) of DBS, and is associated with reduced Cg25 metabolic activity. The NAcc is involved in abnormal motivations and reward processes in MDD, and NAcc DBS for 1-4 years has demonstrated sustained antidepressant effects in 45% of patients (Bewernick et al., 2012) . VAC DBS for up to four years has shown a response rate of 40% at six months and 53.3% at last follow-up (Malone et al., 2009 ).
However, due to small sample sizes of <20 and relatively few studies, it is unclear which of these targets is most effective in producing a positive outcome. Furthermore, even though these targets seem promising, a response to DBS does not occur in all patients. Since mood effects are not observed in all patients with either target, it might be possible that combined stimulation of both targets will achieve better clinical results in patients with insufficient response to stimulation of only one target. Additionally, previous studies have focused on either short-term chronic effects after one week of DBS in MDD (Schlaepfer et al., 2008) , or long-term chronic effects after three months to six years (Bewernick et al., 2010 (Bewernick et al., , 2012 Kubu et al., 2013; Lozano et al., 2008; Malone et al., 2009; Mayberg et al., 2005; Millet et al., 2014) . Comparison of acute effects that appear within hours with chronic effects would help to clarify possible differences in immediate and adaptive longer-term effects of DBS.
Positron emission tomography (PET) using The present study aimed to compare stimulation of SGC (Cg25 or Cg24), VAC/NAcc (VAC or NAcc), and a combination of these targets, in the same TRD patients using [ 15 O]water PET, focusing on chronic changes in rCBF and changes in rCBF associated with acute interruption of DBS for two hours. Choice of stimulation site (SGC or VAC/NAcc) was made in a block-randomised, singleblind fashion. Patients received stimulation of this site for at least three months before switching stimulation to the other single site for at least three months, then switching to the combination of both sites for at least a further three months. At each site, if remission occurred or clinical improvement was assessed as sufficient, the stimulation site was not switched. Secondary outcome measures included clinical questionnaires to characterise effects of DBS on depressive symptoms and functional outcomes.
We hypothesised that: (a) either DBS target would produce a significant improvement in some TRD patients; (b) combined stimulation would be effective in patients for whom one target was not sufficient; (c) acute and chronic changes in rCBF associated with DBS would be prominent and would differ from each other; and (d) clinical improvement would be associated with rCBF changes in brain regions relevant to depression.
Methods and materials

Patients
Eight patients were enrolled to the study, had pre-surgical measurement of baseline rCBF and implantation of DBS electrodes (see Table 1 for demographics and clinical characteristics). One patient required early removal of electrodes due to infection and was withdrawn from the study before the first follow-up PET scan. Therefore, seven patients with treatment refractory unipolar MDD (five female; age range 31-58 years; mean±standard deviation (SD): 48±9 years) received [ 15 O]water PET (pre-surgical and three subsequent occasions during DBS). Patient suitability was jointly assessed by a senior psychiatrist (ALM) and neurosurgeon (NKP) at the University of Bristol, UK. Referrals came from the patients' psychiatric team who were aware of the protocol but not directly involved in the study. If there were any doubts on inclusion criteria, further opinion was sought from one of a panel of three senior psychiatrists who interviewed patients separately.
Patients were included if they had MDD and had not responded to treatments including: (a) cognitive behavioural therapy (CBT); (b) antidepressants from three different classes in British National Formulary doses (Joint Formulary Committee, 2015) ; and (c) lithium augmentation. Furthermore, patients had to have failed to respond to two courses of electroconvulsive therapy (ECT), or to only have responded to maintenance ECT, or to not have responded to the first course of ECT and were unwilling to have a further course. They were required to have a Montgomery-Asberg Depression Rating Scale (MADRS) score of ≥22 (moderatelyseverely depressed) on enrolment. Additional inclusion criteria were being physically fit and having no suicidal intent. Exclusion criteria included: history of head trauma, dementia, cerebral infarcts, incapacity to consent, inability to carry out the study, mood incongruent psychotic phenomena, and drug and/or alcohol addiction. (2000). Participants gave their written informed consent prior to study participation.
Surgical procedure
The surgical procedure was performed under general anaesthesia, using a modified Leksell stereotactic frame (Elekta, Stockholm, Sweden). Patients were implanted with four deep brain stimulating electrodes (Model 3387, Medtronic, Minneapolis, Minnesota, USA): two electrodes were bilaterally positioned with all four contacts in the white matter of the SGC (Cg25 and Cg24), and two electrodes were bilaterally positioned with two contacts in the VAC and two distal contacts in the NAcc, 5 mm anterior to the anterior commissure. Subclavicular programmable neurostimulators were implanted, either non-rechargeable (Kinetra; 7428) or rechargeable (Activa RC; 37601).
DBS electrode positioning and planning was made on high-resolution MRI. Implantable guide tubes and stylettes were stereotactically implanted to the planned coordinates. DBS leads were introduced down the implanted guide-tubes into the targets replacing the stylettes, whose position was verified on perioperative highresolution MRI, enabling accurate knowledge of the electrode contacts within the target (Khan et al., 2010; Patel et al., 2007) (Figure 1 ). Following the operation, a period of one-week recovery was allowed to minimise any effect from post-operative oedema.
Stimulation procedures
Overview of treatment periods. For each patient, DBS was given in three sequential treatment periods over a total period ranging from 16-45 months. The exact duration was determined by each patient's clinical response and requirements. During each period (both sites singly and in combination) DBS was administered bilaterally for at least three months before switching (Table 2 ). More precisely, the treatment periods were as follows:
Treatment period 1: After post-operative recovery, appropriate stimulation contacts and frequencies were assessed for either SGC (selection of either Cg25 or Cg24) or VAC/ NAcc (selection of either VAC or NAcc). The choice of SGC or VAC/NAcc as first stimulation site was made in a blockrandomised fashion.
Treatment period 2: After at least three months, stimulation was switched to the alternate site unless the patient had achieved remission (MADRS score ≤8 for at least two months). Specifically, if during the first stimulation block the SGC (either Cg25 or Cg24) was stimulated, stimulation would now be moved to either VAC or NAcc, and vice versa.
Treatment period 3:
After a further minimum of three months, patients received DBS of a combination of targets unless they had achieved remission in one of previous treatment periods.
Criteria for determining stimulation sites and frequencies
Appropriate stimulation contacts and frequencies were assessed over a period of up to two weeks. Each contact was tried in turn for up to two days. Final selection was of the contacts showing most improvement on a mood-diary and a blinded mental-state examination. Stimulation was always bilateral. Patients were blind to the order of stimulation, to contacts selected, and to any 'off' period in the contact selection process.
Clinical assessments
Secondary outcome measures of depressive symptoms and function comprised the MADRS (Montgomery and Asberg, 1979), Hamilton Depression Rating Scale 17 items (HAM-D 17) (Hamilton, 1960) , and Global Assessment of Function Scale (GAF) (Hall, 1995) . Both the MADRS and HAM-D measure severity of depression, with lower scores indicating lower severity. For the GAF, higher scores indicate less impaired social, occupational, and psychological functioning.
Response to DBS was defined as a reduction in MADRS score from baseline of ≥50%, and remission as a MADRS score of ≤8. The delay between clinical assessments and PET scans was as short as practicable, given that they were conducted in different cities, but not more than 72 h.
Image acquisition
A baseline, pre-operative, high-resolution T 1 -weighted image was acquired using a 1.5T Philips Achieva scanner. PET imaging was performed using a High-Resolution Research Tomograph (Siemens).
[ 15 O]water PET scans were acquired at baseline and at the end of each treatment period. At baseline, four repeat scans were acquired in each patient. For each of the other three PET scan visits, three repeat scans were acquired when stimulation was switched on and three when stimulation had been switched off for 120 min (Table 2) .
Each scan consisted of an intravenous injection of approximately 370 MBq of [ 15 O]water using a radio water generator (HIDEX, Turku, Finland). The data over the 90-second period following activity-arrival in the brain was acquired and reconstructed using 3D ordinary Poisson ordered subset expectation maximization (OSEM3D-OP) with 16 subsets and four iterations (Comtat et al., 2004) . The images were subsequently used as a relative surrogate for rCBF. Scans were spaced a minimum of 10 min apart to ensure that radioactivity from the previous scan had decayed to background level.
Image pre-processing
Pre-processing was performed using SPM8 (Statistical Parametric Mapping, Wellcome Department of Imaging Neuroscience, Institute of Neurology, London, UK). For each patient, PET scan images were realigned to each other and used to create a mean image (rigid body, 5 mm full width at half maximum [FWHM] pre-registration smooth). This mean image was then used to co-register subjects PET data to the subject's T 1 -weighted image (rigid body, normalised mutual information) which in turn was spatially normalised to the standard T 1 -weighted Montreal Neurological Institute (MNI) PET template in SPM8 (International Consortium for Brain Mapping [ICBM] regularised affine + nonlinear [frequency cut-off=25, iterations=16, regularisation=1]). Subsequently each PET image was resliced into 2 mm isotropic voxel MNI space images and smoothed with a 6 mm FWHM Gaussian kernel.
Data analysis
Whole-brain analysis was performed within SPM8 using a flexible factorial design with interactions between target (Cg25, Cg24, VAC, NAcc, combination of >1 target stimulated) and activation state (baseline, stimulation on, stimulation off). Clusters of voxels were considered significant at a family-wise error (FWE) corrected cluster-size threshold of pFWEc<0.05 and a height threshold of pFWE<0.05. Follow-up analysis tested: (a) chronic effects of SGC (Cg25+Cg24), VAC/NAcc (VAC+NAcc), and combined target stimulation, regardless of whether stimulation was switched on or off; and (b) changes in rCBF between baseline and last PET scan, irrespective of stimulation site and whether stimulation was on or off.
Furthermore, region data were visually inspected by focusing on intensity-normalised data, i.e. voxels which changed relative to average values in the brain (regional/global). More precisely, we inspected the mean concentration of radioactivity in the brain over a period of 90 s following its arrival, and used this as a surrogate for rCBF. Here, we will refer to this surrogate as rCBF. Regions of interest (ROIs) were derived from the n30r83 version of the probabilistic brain-atlas (Hammers et al., 2003; Rylands et al., 2012) , and were selected based upon significant results found in the afore-mentioned whole-brain analysis.
Results
Effects of DBS on rCBF: whole-brain analysis
Baseline versus stimulation on. Compared to baseline, significant rCBF decreases in the NAcc were seen after stimulation of both Cg25 (MNI coordinates x, y, z (in mm) = 14, 12, -1; cluster size (k) =31; pFWEc<0.001) and Cg24 (14, 10, -7; k=23; pFWEc<0.001). With combined target stimulation, rCBF increased in the post-central gyrus (44, -24, 61; k=113; pFWEc<0.001) and parietal sub-gyral area (24, -42, 57; k=60; pFWEc<0.001).
Baseline versus stimulation off. Compared to baseline, significant rCBF increases were seen in the post-central gyrus (44, -24, 59; k=84; pFWEc<0.001) and parietal sub-gyral area (26, -40, 53; k=35; pFWEc<0.001) when combined stimulation was acutely switched off, similar to the findings in baseline versus stimulation on (above). A significant rCBF increase in the dorsal anterior cingulate (ACC) was seen when chronic VAC stimulation was acutely switched off (10, 32, 19; k=57; pFWEc<0.001).
Acute interruption of chronic stimulation:
On versus off. When comparing rCBF on chronic stimulation with rCBF after stimulation had been turned off for 120 min (acute effects), only one statistically significant result was found: rCBF increased in the dorsal ACC when VAC stimulation was switched off (12, 30, 31; k=31; pFWEc<0.001) . This is similar to the rCBF increase in VAC seen between baseline and stimulation off (above).
Further details of all significant DBS effects comparing baseline with on and off, and on versus off, stratified by target stimulated (Cg25, Cg24, VAC, NAcc, and any combination of more than one target stimulated) are presented in Supplementary Material 1. DBS signal changes compared to baseline on the normalised SPM8 glass brain are presented in Supplementary Material 2.
Effects of chronic stimulation of each area. In the wholebrain results above, similar findings were apparent when comparing stimulation on and off with baseline, and few effects were seen when chronic stimulation was acutely interrupted. We therefore decided to run additional analyses, focusing on effects between: (a) baseline and SGC stimulation (Cg25+Cg24); (b) baseline and VAC/NAcc (VAC+NAcc) stimulation, and (c) baseline and combined target stimulation, all regardless of whether stimulation was on or off. See Table 3 for the results.
Region data on NAcc
The most consistent finding after visually inspecting the ROI data was a decrease in rCBF (regional/global CBF) in TRD patients in the NAcc. This decrease was apparent irrespective which target was stimulated. Also, differences between both baseline and on, and baseline and off were overall more pronounced than differences between on and off (Figure 2) .
We also see a decrease in NAcc rCBF when inspecting the data over time (from baseline to visit 4), regardless of target stimulation (Figure 3) . Furthermore, post hoc whole-brain SPM analysis of DBS signal changes between baseline and visit 4, when target stimulation is optimised, showed a similar decrease in NAcc, and a decrease encompassing Cg25, ACC (ba32) and the interpeduncular region of the ventral midbrain (Figure 4) .
Effects in PFC and clinical outcomes
Over the course of the study, three patients remitted, two responded but did not remit (non-remitters), and two were nonresponders. When visually inspecting the ROI data over time, there was an increase in rCBF bilaterally in the PFC. The data indicated that remitters had higher rCBF in the PFC both at baseline and all subsequent visits compared to non-remitters and nonresponders ( Figure 5 (a) and (b)).
Although less clear, when looking at the raw data of clinical outcome measures, remitters also seemed to have lower MADRS and HAM-D scores at baseline (indicating less severe depression) (Figure 5(c) and (d) ). They also had higher GAF scores (A) And on a single-subject CH2-masked template (B) A decrease in relative cerebral blood flow (CBF) changes (rCBF/ gCBF) is apparent in a large bilateral cluster encompassing the nucleus accumbens, Cg25 and the ACC (ba32), extending to the interpeduncular region of the ventral midbrain. Clusters of voxels were considered significant at a cluster size threshold and height threshold of pFWE<0.05. ba: Brodmann area; fr: frontal; L: left.
(indicating less impaired social, occupational, and psychological functioning) during baseline ( Figure 5(e) ).
Discussion
The present study was conducted to compare stimulation of SGC (Cg25 or Cg24), VAC/NAcc (VAC or NAcc) and a combination of these targets in the same TRD patients, focusing on both acute and chronic changes in rCBF using [ 15 O]water PET. DBS was associated with decreased rCBF at the sites of stimulation and in a range of distant regions including frontal and orbitofrontal cortical regions and thalamus (Table 3) . Most prominently, a decrease in NAcc was seen with all three stimulation conditions. Acute interruption of chronic stimulation was not associated with prominent rCBF changes (Supplementary Material 1) . Five of seven patients responded to DBS and of these, three remitted. These results are similar to previous studies (Bewernick et al., 2010; Lozano et al., 2008) . Remitters had higher rCBF in PFC before and throughout DBS ( Figure 5 ).
Acute effects
The lack of prominent changes after acute interruption of chronic stimulation might be caused by the relatively short time (2 h) that stimulation was switched off before scanning. A previous study suggests that beneficial DBS effects in dystonia may persist after stimulation is switched off, with only a slow worsening of symptoms returning to pre-operative levels after 48 h of stimulation (Grabli et al., 2009) . In agreement, a case report of a TRD patient under DBS of the lateral habenula showed that after stimulation was accidentally switched off, relapse occurred a couple of days later (Sartorius et al., 2010) . One might however expect that stimulation interruption would cause acute changes in rCBF even when not apparent in behavioural response. But in this study, in general, this was not observed. Nonetheless, such acute rCBF changes may still occur when switching stimulation acutely on.
Effects by area of stimulation
Effects on frontal regions and thalamus. Local rCBF decreases were apparent in Cg25 after SGC stimulation and in NAcc after SGC, VAC/NAcc, and combined stimulation. Increases in both glucose metabolism and rCBF in SGC have been seen in MDD, which normalise with remission and antidepressant treatment (Drevets et al., 2008; Mayberg et al., 1999; Sacher et al., 2012) . In more distant regions, decreases in medial frontal gyrus and thalamus were seen with SGC and combined stimulation, and in the middle frontal gyrus (MFG) with SGC and VAC/NAcc stimulation. Decreases in the orbitofrontal cortex were present after combined stimulation. In keeping with this, decreases in the medial frontal gyrus and orbitofrontal cortex after DBS have previously been reported with both Cg25 (Lozano et al., 2008; Mayberg et al., 2005) and NAcc stimulation (Bewernick et al., 2012; Millet et al., 2014) . Similar effects have also been observed after CBT, suggesting that SGC and combined DBS target a mood-regulatory network involved in depression (Mayberg et al., 2005) . Additionally, the effects seen in the MFG are consistent with past studies regarding Cg25 stimulation (Lozano et al., 2008) , and in the thalamus regarding NAcc stimulation (Bewernick et al., 2010; Schlaepfer et al., 2008) .
Increases in rCBF were only observed after combined DBS, with effects in MFG, pre-and postcentral gyrus, and inferior and superior gyrus. Increases in MFG are comparable to previous Cg25 and NAcc stimulation (Lozano et al., 2008; Schlaepfer et al., 2008) . Precentral and superior gyrus increases are similar to NAcc stimulation in earlier studies (Bewernick et al., 2010; Millet et al., 2014) . Increases in prefrontal regions, such as the inferior frontal gyrus, have been reported with Cg25 stimulation and are similar to antidepressant patterns seen with medication (Mayberg et al., 2000 (Mayberg et al., , 2005 .
Taken together, our data are consistent with previous studies and indicate that abnormalities observed in MDD, such as hypoand hyperactivity in brain regions (Morishita et al., 2014) , are reversed by DBS. Our results show that the targets used have more commonalities than differences between them with an overlap in effects between stimulation targets, which is also present when comparing Cg25 and NAcc literature, suggesting a similar response-pattern irrespective of target area.
Effects on NAcc.
A decrease in NAcc rCBF is also apparent in the region data with all target stimulations (Figure 2) , consistent with the NAcc results of our whole-brain analysis (Table 2) . Furthermore, no clear difference between stimulation on or off can be seen which is again consistent with earlier analysis (Supplementary Material 1). When looking at the response pattern over time, the rCBF decrease in the NAcc remains (Figure 3) which is also consistent with whole-brain analysis (Figure 4 ). This decrease in NAcc rCBF does not appear to differ between responders and non-responders, suggesting that this decrease is either not directly linked to improvement of MDD symptoms or, on its own, is insufficient for response.
Previous DBS studies do not report NAcc decreases. In fact, an increase in NAcc metabolism has been reported after one week of NAcc DBS (Schlaepfer et al., 2008) . However, this increase did not remain after chronic DBS, suggesting that it might have been a short-term response to the surgical procedure (Bewernick et al., 2012) .
Frontal cortical changes predictive for response and marker for response
Our stimulation procedures were designed to ensure that patients received appropriate DBS of either SGC or VAC/NAcc during treatment periods 1 and 2. During treatment period 3, patients received combined DBS treatment or, when remission occurred in previous periods, the best treatment so far. It was therefore expected that improvements should be most prominent after the third treatment period. Indeed, inspecting the region data over time shows increases in PFC between baseline and last PET scan ( Figure 5 ). MDD is associated with decreased PFC activity and increases after DBS are consistent with past studies, as well as similar to effects of antidepressant medication (Mayberg et al., 2000 (Mayberg et al., , 2005 Schlaepfer et al., 2008) . Activity changes in the PFC thus seem to be a marker of antidepressant response (Riva-Posse et al., 2014) .
Our data show that remitters had higher rCBF levels in the PFC during all visits, including baseline, compared to non-remitters and non-responders. Remitters also had relatively better clinical outcome measures at baseline and at the last PET visit. Higher frontal cortical rCBF might thus be predictive for response. However, even though non-responders failed to cross the clinical threshold, effects of DBS were apparent. It might therefore be that DBS on its own is insufficient or that more time on stimulation is required to reach clinical response in these patients, which are in this study characterised by low PFC rCBF.
Limitations
A limitation of our study is the small sample size that provides insufficient power to clearly determine clinical efficacy, making our findings preliminary. Nonetheless, of the seven patients, three reached remission and a further two responded following DBS. Given the documented low and poorly sustained response rates in TRD (Dunner et al., 2006; Luigjes et al., 2013) , these are encouraging results. In this study, patients were required to have failed to respond to two courses of ECT, or responded only to maintenance ECT, or did not respond to a first course of ECT and were unwilling to have a further course. Our cohort of patients therefore represents a particularly treatment-refractory group. Recently proposed standardised definitions of TRD, including 'Stage II treatment-resistant depression' (Conway et al., 2017) and 'Multiple-therapy-resistant-Major Depressive Disorder' (MTR-MDD) (McAllister-Williams et al., 2017 (in press) ), which may warrant more invasive or higher-risk antidepressant treatments such as surgical interventions, either do not include the need for prior ECT (Stage-II TRD) or require nonresponse to one adequate trial of ECT (MTR-MDD). Standardisation of inclusion criteria should improve the comparability of future studies. Additionally, it might have been better to determine the ideal stimulation sites and frequencies for each patient over a longer period than two days per contact, since it may take longer to see the ideal effects of DBS. However, we did notice differences in improvements between stimulation sites and frequencies after trying each contact in turn for up to two days, making this approach nonetheless an improvement and appealing approach for future DBS studies. Another limitation is that stimulation was always switched off after chronic stimulation, though acute changes might occur if stimulation were to be acutely switched on after being off. Global intensity-normalization was used, meaning that rCBF changes in one direction could be due to changes in the opposite direction of the complementary region. Furthermore, no sham stimulation phase was used because of possible symptom aggravation. Indeed, previous studies have changed their design after study-initiation leaving out sham conditions because of significant worsening of symptoms (Bewernick et al., 2010 (Bewernick et al., , 2012 Holtzheimer et al., 2012) . Moreover, there is evidence that placebo response rates are lower in patients with severe depression (such as in our cohort) compared to patients with mild depression (Schatzberg and Kraemer, 2000) . Also, for each of our patients different stimulation contacts and frequencies for stimulation were most effective, arguing for specificity of stimulation (Lozano et al., 2008) .
Conclusion
We conclude that DBS improves TRD in the majority of patients. Acute effects of short-term DBS interruption are small compared to chronic stimulation effects, indicating that acute effects are more subtle than hypothesised. A consistent decrease in rCBF is observed in the NAcc with DBS regardless of stimulation site, suggesting that this may be a common pathway mediating effects of DBS in TRD, although it is not clearly linked to improvement in severity of depression. Our data additionally suggest that treatment response is reached in patients with higher baseline prefrontal rCBF. Further evaluation is necessary to confirm whether higher frontal rCBF could be a predictive biomarker of treatment response, which might help to optimise patient selection for DBS in MDD.
